Related Experiment Video
Updated: Feb 3, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric
Jennifer Hammer, Emmanuel Seront1, Steven Duez2
1Center for Vascular Anomalies, Institut Roi Albert II, Department of Medical Oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
Background:
Extensive and complex vascular malformations often cause chronic pain and severe functional restraint. Conventional treatments, such as surgery and/or sclerotherapy, are rarely curative, underscoring the great need for new therapeutic modalities. Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway. The purpose of this prospective study was to assess the efficacy and safety of this treatment in patients with extensive or complex slow-flow vascular malformations.
Methods:
Sirolimus was administered orally on a continuous dosing schedule with pharmacokinetic-guided target serum concentration level of 10 to 15 ng/ml. Patients were seen every month for the first three months and subsequently every three months. The primary endpoints were safety and efficacy, based on clinical, biological and radiological evaluations, as well as a quality of life questionnaire.
Results:
Nineteen patients, from 3 to 64 years old, with lymphatic (LM), venous (VM) or complex slow-flow malformations, refractory to standard care, were enrolled and received sirolimus continuously. After 12 months of follow-up, 16 patients were available for assessment of efficacy and safety: all had a significant and rapid improvement of their symptoms and quality of life. In two patients, sirolimus treatment permitted sclerotherapy and surgery, initially evaluated unfeasible. Sirolimus was well tolerated, with mucositis as the most common (10% of patients) grade 3 adverse event.
Conclusions:
Sirolimus was efficient in extensive LM, VM and/or complex malformations that were refractory to conventional treatments and was well tolerated.
Insights
Sirolimus effectively treats extensive vascular malformations, improving patient quality of life and symptoms. This drug is well-tolerated and offers a new therapeutic option for complex cases.
Area of Science:
- Vascular Biology
- Pharmacology
- Medical Therapeutics
Background:
- Extensive vascular malformations cause chronic pain and functional limitations.
- Conventional treatments like surgery and sclerotherapy are often ineffective.
- Sirolimus shows promise in inhibiting the PI3K/AKT/mTOR pathway to manage these malformations.
Purpose of the Study:
- To evaluate the efficacy and safety of sirolimus for extensive or complex slow-flow vascular malformations.
- To assess improvements in patient symptoms, quality of life, and treatment outcomes.
Main Methods:
- Prospective study involving oral sirolimus administration with pharmacokinetic-guided dosing (10-15 ng/ml).
- Monthly follow-up for three months, then quarterly.
- Primary endpoints included safety and efficacy via clinical, biological, radiological, and quality of life assessments.
Main Results:
- Nineteen patients (3-64 years) with refractory lymphatic (LM) or venous malformations (VM) received sirolimus.
- After 12 months, 16 patients showed significant symptom and quality of life improvement.
- Sirolimus enabled previously unfeasible surgery/sclerotherapy in two patients; it was well-tolerated with mucositis as the most common grade 3 adverse event.
Conclusions:
- Sirolimus is effective for extensive LM, VM, and complex malformations resistant to conventional therapies.
- The treatment demonstrates good tolerability.
- Sirolimus represents a viable therapeutic option for challenging vascular malformations.
Related Concept Videos
Gene Evolution - Fast or Slow?
In contrast, regions which code...
Gene Evolution - Fast or Slow?
Imaging Studies VII: Vascular Imaging
Self-Efficacy
Phase Transitions
Seedless Vascular Plants

